GSK Plc agreed another deal with British biotech Relation Therapeutics Ltd. to use artificial intelligence to speed up drug development. The agreement, which could see Relation paid up to $110 million ...
About half a year into his tenure as GSK’s CEO, Luke Miels is launching a three-year restructuring to navigate the British pharma through upcoming patent cliffs and achieve over 40 billion pounds ...
GSK GSK-2.10%decrease; down pointing triangle agreed to buy U.S. cancer-drug developer Nuvalent for $10.6 billion, the British pharmaceutical company’s latest move to bolster its oncology business.
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK said Tuesday it would ...
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides. The British drugmaker is paying $55 million upfront to China’s ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
GSK (GSK) reported better-than-expected financials for Q1 2026 on Wednesday as sales from its HIV and cancer medicines offset a sales decline for its general medicines, including its respiratory ...
GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an antibody-drug conjugate (ADC). That deal, signed back in 2022, centered on XMT ...
GSK (GSK) is preparing a high-stakes push into oncology, lining up five late-stage trials at once for a promising cancer drug as new CEO Luke Miels seeks to reshape the company’s historically cautious ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. GSK (LSE:GSK) has received FDA approval for Lynavoy (linerixibat), the first ...
GSK struck a $950 million deal to buy Canada’s 35Pharma, a biopharmaceutical company developing cardiopulmonary treatments, as the U.K. drugmaker seeks to bolster its exposure to diseases linked to ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Building up its base of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results